Skip to Main Content

Paper Details

Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Am Heart J
39
2021
AHF, Dapagliflozin, NT-proBNP, Patients, acute heart failure, cardiovascular death, chronic heart failure, dapagliflozin, diabetes, diabetic, furosemide, glucose, heart failure, hyper/hypoglycemia, hypovolemic hypotension, insulin, ketoacidosis, patients, sodium, sodium-glucose cotransporter-2, type 2 diabetes
Acute Disease, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Disease Progression, Glucosides, Heart Failure, Hospital Mortality, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Hypotension, Hypovolemia, Insulin, Natriuresis, Natriuretic Peptide, Brain, Patient Readmission, Peptide Fragments, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic, Sodium Potassium Chloride Symporter Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome, Weight Loss
Author NameAffiliation
Zachary L CoxDepartment of Pharmacy Practice, Lipscomb University College of Pharmacy, TN Department of Pharmacy, Vanderbilt University Medical Center
Sean P CollinsVanderbilt University Medical Center
Mark F AaronSaint Thomas West Hospital
Gabriel A HernandezUniversity of Mississippi Medical Center
A Thomas McRae IiiTriStar Centennial Medical Center
Beth Towery DavidsonTriStar Centennial Medical Center
Michael FowlerVanderbilt University Medical Center
Christopher J LindsellVanderbilt University Medical Center
Frank E Harrell JrVanderbilt University Medical Center
Cathy A JenkinsVanderbilt University Medical Center
Christina J KampeVanderbilt University Medical Center
Karen F MillerVanderbilt University Medical Center
William B StubblefieldVanderbilt University Medical Center
JoAnn LindenfeldVanderbilt University Medical Center
  • 1 - 14

Datasets

Release 1.2